Cryoglobulinemia
For patient information page click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Synonyms and keywords: Cryoglobulinaemia
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Ayesha A. Khan, MD[3]
Overview
Cryoglobulinemia is the presence of high amount of heavy globulins (e.g. IgM) in the bloodstream which thicken or gel on exposure to cold. Cryoglobulins are circulating immunoglobulins or proteins that become insoluble at less than 4 degrees Celsius. The reaction is reversible; redissolution occurs at 37 degrees Celsius. Such proteins are called cryoglobulins. Cryoglobulinemia can lead to a medium-sized vessel vasculitis due to vascular deposition of circulating immune complexes. This leads to the triad of palpable purpura, arthralgias and peripheral neuropathy. The relationship of cryoglobulins and hepatitis C infection as well as B cell neoplasia provides an interesting link between infection, autoimmune disease and lymphoproliferative disorders.
Classification
Pathophysiology
Causes
Differentiating cryoglobulinemia from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Findings
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
References
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Overview
In 1966, Meltzer and Franklin were the first ones to describe Meltzer triad which includes following clinical manifestations, purpura, arthralgia, and weakness.
Historical Perspective
The historical perspective of cryoglobulinemia is as follows:[1][2]
- In 1966, Meltzer and Franklin were the first ones to describe Meltzer triad which includes following clinical manifestations, purpura, arthralgia, and weakness.
- This triad of clinical manifestations was seen in the patients having essential mixed cryoglobulinemia.
References
- ↑ Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N (1966). “Cryoglobulinemia–a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity”. Am J Med. 40 (6): 837–56. PMID 4956871.
- ↑ Monti G, Galli M, Invernizzi F, Pioltelli P, Saccardo F, Monteverde A; et al. (1995). “Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias”. QJM. 88 (2): 115–26. PMID 7704562.
Classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Overview
Cryoglobulinemia is classically grouped into three types according to the Brouet classification. These are type 1, type 2 and type 3.
Classification
Cryoglobulinemia is classically grouped into three types according to the Brouet classification.[1]
| Types of cryoglobulinemia | |||
|---|---|---|---|
| Associated diseases | Type 1 | Type 2 | Type 3 |
|
|
| |
Type I
- Type I is is a monoclonal immunoglobulin and is most commonly encountered in patients with a plasma cell dyscrasia such as multiple myeloma or Waldenström macroglobulinemia.[2]
- It can lead to a glomerulopathy that is distinct from light chain disease in amyloidosis.
Type II
- Type II is essential mixed cryoglobulinemia and the cryoglobulins are a polyclonal IgG and a momoclonal IgM rheumatoid factor directed against IgG.
- Epstein-Barr Virus (EBV), HIV and Hepatitis B have been implicated but the majority is due to Hepatitis C (HCV).
Type III
- Type III is also a mixed cryoglobulinemia (MC) where both the IgG and IgM are polyclonal.
- It is seen in various autoimmune disorders and lymphoreticular disease as well as hepatitis C in almost 50%.
References
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]Feham Tariq, MD [3]
Overview
Cryoglobulins are proteins (single or mixed immunoglobulins) that precipitate from serum and plasma when cooled. They are produced due to chronic immune system activation and lymphoproliferation. Cryoglobulins have a tendency to redissolve on rewarming.
Pathophysiology
- Cryoglobulins are proteins (single or mixed immunoglobulins) that precipitate from serum and plasma when cooled.
- They are produced due to chronic immune system activation and lymphoproliferation.
- Cryoglobulins have a tendency to redissolve on rewarming.
- The pathogenesis of cryoglobulinemia differs slightly based on the type of disorder and disease associations.
- The following are the major mechanisms involved in the pathogenesis of cryoglobulinemia:
Type I cryoglobulinemia (Monoclonal immunoglobulin)
Key background associations
- Type I cryoglobulinemia is usually seen in patients suffering from disorders of lymphoproliferation such as:
- Multiple myelomas (MM)
- Monoclonal gammopathy of undetermined significance (MGUS)
- Waldenstrom’s macroglobulinemia
- Chronic lymphocytic leukemia (CLL)
Mechanisms leading to precipitation of immunoglobulins (Ig)
The solubility of proteins depends upon concentration, hydrophobicity, size and surface charge, as well as the solution temperature, pH and ionic strength. The following mechanisms have been proposed to be implicated in the precipitation of immunoglobulins in patients suffering from type I cryoglobulinemia:
(a) Chronic immune stimulation
- The lymphoproliferative and hematological disorders listed above lead to chronic activation of the immune system and production of higher concentrations of monoclonal immunoglobulins (usually IgG or IgM) at temperatures below 37 degrees celcius.
(b) Aggregation of immunoglobulins
- Self aggregation through Fc fragment of immunoglobulins is the proposed mechanism of production of cryoglobulins in type I cryoglobulinemia
(i) Modification of Ig heavy (H) and light (L) chains
- An abnormal glycosylation event in the heavy chain hypervariable region apparently leads to precipitation of immunoglobulins in type I cryoglobulinemia.[1]
(ii) Reduced concentration of sialic acid
- Increased content of hydrophobic amino acids, decreased tyrosine and sialic acid residues has been known to lead to decreased solubility of immunoglobulins (Ig).[2]
(iii) Deficiency of galactose in the Fc portion of the Ig
- Decreased galactose concentration in the Fc portion of immunoglobulins leads to decreased plasma solubility of immunoglobulins.[3]
- The terminal sialylation of these proteins is dependent on the presence of galactose residues, hence decreased galactose leads to decreased sialylation, which in turn promotes precipitation of immunoglobulins.[4]
- The decreased glycosylation has also been linked to the increased nephrophilic nature of cryoglobulins.
(iv) Somatic Ig mutations
- Somatic hypermutation in the variable regions of the heavy (VH) and light chains (VL) may also contribute to the insolubility of immunoglobulins.
- Increased intraclonal VH and/or VL gene diversity has been shown to be present in various patients suffering from hepatitis C associated mixed cryoglobulinemia.[5]
(v) Non-specific Fc–Fc interactions
It is important to note that these two different, yet highly representative, clinical syndromes generally reflect different types of underlying CG:
- Hyperviscosity is typically associated with CG due to hematological malignancies and monoclonal immunoglobulins.
- “Meltzer’s triad” of palpable purpura, arthralgia and myalgia is generally seen with polyclonal CGs seen in essential-, viral-, or connective tissue disease-associated CG.
- MC is closely associated with hepatitis C infection and is thought to activate B lymphocytes by binding to CD81.
- 80-95% of patients with MC have circulating anti-HCV antibodies or circulating HCV RNA in the serum or within the cryoprecipitate.
- Polyclonal IgG anti-HCV have been noted in the cryoprecipitate as well.
- Approximately 50% of patients with chronic hepatitis C and 15% with hepatitis B will have circulating MC (1/2 Type II, 2/3 Type III).
- It is unclear what the antigen trigger is for production of the MC, but it is though that the hepatitis C viral RNA itself may be the factor since it is found in high quantities in the cryoprecipitate.
References
- ↑ “Atypical glycosylation of an IgG monoclonal cryoimmunoglobulin”.
- ↑ Tomana M, Schrohenloher RE, Koopman WJ, Alarcón GS, Paul WA (March 1988). “Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases”. Arthritis Rheum. 31 (3): 333–8. PMID 3358797.
- ↑ Trendelenburg M, Schifferli JA (August 2003). “Cryoglobulins in chronic hepatitis C virus infection”. Clin. Exp. Immunol. 133 (2): 153–5. PMC 1808770. PMID 12869018.
- ↑ Otani M, Kuroki A, Kikuchi S, Kihara M, Nakata J, Ito K, Furukawa J, Shinohara Y, Izui S (November 2012). “Sialylation determines the nephritogenicity of IgG3 cryoglobulins”. J. Am. Soc. Nephrol. 23 (11): 1869–78. doi:10.1681/ASN.2012050477. PMC 3482736. PMID 23024299.
- ↑ “www.bloodjournal.org” (PDF).
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Overview
Common causes of cryoglobulinemia are primarily hematologic, oncologic, and rheumatic. Less commonly, cryoglobulinemia can be caused by infections such as HIV or Hepatitis C.
Causes
Common Causes
The common causes of cryoglobulinemia are as follows:[1][2][3][4]
- B-cell hyperactivation
- B-cell hyperproliferation
- Glomerulonephritis
- Hepatitis c
- Hypersensitivity vasculitis
- Myeloma
- Primary macroglobulinemia
- Rheumatoid disease
- Systemic lupus erythematosus
- Waldenstrom macroglobulinaemia
Causes by Organ System
| Cardiovascular | Hypersensitivity vasculitis, Raynaud’s phenomenon |
| Chemical/Poisoning | No underlying causes |
| Dental | No underlying causes |
| Dermatologic | Purpura |
| Drug Side Effect | No underlying causes |
| Ear Nose Throat | Sjögren’s syndrome |
| Endocrine | No underlying causes |
| Environmental | No underlying causes |
| Gastroenterologic | No underlying causes |
| Genetic | Sjögren’s syndrome |
| Hematologic | B-cell hyperactivation , B-cell hyperproliferation, Leukemia, Multiple myeloma, Myeloma, Primary macroglobulinemia, Purpura, Raynaud’s phenomenon |
| Iatrogenic | No underlying causes |
| Infectious Disease | Hepatitis c, Hiv, Mycoplasma pneumonia |
| Musculoskeletal/Orthopedic | No underlying causes |
| Neurologic | No underlying causes |
| Nutritional/Metabolic | No underlying causes |
| Obstetric/Gynecologic | No underlying causes |
| Oncologic | Leukemia, Multiple myeloma, Myeloma, Primary macroglobulinemia, Waldenström macroglobulinaemia |
| Ophthalmologic | No underlying causes |
| Overdose/Toxicity | No underlying causes |
| Psychiatric | No underlying causes |
| Pulmonary | Mycoplasma pneumonia |
| Renal/Electrolyte | Glomerulonephritis |
| Rheumatology/Immunology/Allergy | Arthropathy, Rheumatoid arthritis, Rheumatoid disease, Systemic lupus erythematosus |
| Sexual | Hiv |
| Trauma | No underlying causes |
| Urologic | No underlying causes |
| Miscellaneous | No underlying causes |
Causes in Alphabetical Order
- Arthropathy
- B-cell hyperactivation
- B-cell hyperproliferation
- Glomerulonephritis
- Hepatitis c
- Hiv
- Hypersensitivity vasculitis
- Leukemia
- Multiple myeloma
- Mycoplasma pneumonia
- Myeloma
- Primary macroglobulinemia
- Purpura
- Raynaud’s phenomenon
- Rheumatoid arthritis
- Rheumatoid disease
- Sjögren’s syndrome
- Systemic lupus erythematosus
- Waldenström macroglobulinaemia
References
- ↑ Scotto G, Cibelli DC, Saracino A, Prato R, Palumbo E, Fazio V; et al. (2006). “Cryoglobulinemia in subjects with HCV infection alone, HIV infection and HCV/HIV coinfection”. J Infect. 52 (4): 294–9. doi:10.1016/j.jinf.2005.05.025. PMID 16026843.
- ↑ Suszek D, Majdan M (2018). “[Cryoglobulins and cryoglobulinemic vasculitis]”. Wiad Lek. 71 (1 pt 1): 59–63. PMID 29558353.
- ↑ Blank N, Lorenz HM (2016). “[Cryoglobulinemic vasculitis]”. Z Rheumatol. 75 (3): 303–15. doi:10.1007/s00393-016-0076-4. PMID 27034078.
- ↑ Ramos-Casals M, Trejo O, García-Carrasco M, Cervera R, Font J (2000). “Mixed cryoglobulinemia: new concepts”. Lupus. 9 (2): 83–91. doi:10.1191/096120300678828127. PMID 10787003.
Differentiating Cryoglobulinemia from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Overview
Cryoglobulinemia should be differentiated from hemolytic uremic syndrome, antiphospholipid syndrome, churg-strauss syndrome, polyarteritis nodosa, microscopic polyangitis and temporal arteritis.
Differentiating Cryoglobulinemia from other Diseases
Cryoglobulinemia should be differentiated from hemolytic uremic syndrome, antiphospholipid syndrome, churg-strauss syndrome, polyarteritis nodosa, microscopic polyangitis and temporal arteritis.
Abbreviations: ABG= Arterial blood gas, ANA= Antinuclear antibody, ANP= Atrial natriuretic peptide, ASO= Antistreptolysin O antibody, BNP= Brain natriuretic peptide, CBC= Complete blood count, COPD= Chronic obstructive pulmonary disease, CRP= C-reactive protein, CT= Computed tomography, CXR= Chest X-ray, DVT= Deep vein thrombosis, ESR= Erythrocyte sedimentation rate, HRCT= High Resolution CT, IgE= Immunoglobulin E, LDH= Lactate dehydrogenase, PCWP= Pulmonary capillary wedge pressure, PCR= Polymerase chain reaction, PFT= Pulmonary function test.
References
- ↑ Vaideeswar P, Deshpande JR (2013). “Pathology of Takayasu arteritis: A brief review”. Ann Pediatr Cardiol. 6 (1): 52–8. doi:10.4103/0974-2069.107235. PMC 3634248. PMID 23626437.
- ↑ Calvo-Romero JM (2003). “Giant cell arteritis”. Postgrad Med J. 79 (935): 511–5. PMC 1742823. PMID 13679546.
- ↑ Stafa A, Leonardi M (2008). “Role of neuroradiology in evaluating cerebral aneurysms”. Interv Neuroradiol. 14 Suppl 1: 23–37. doi:10.1177/15910199080140S106. PMC 3328052. PMID 20557771.
- ↑ Cassiman C, Casteels I, Stalmans P, Legius E, Jacob J (2017). “Optical Coherence Tomography Angiography of Retinal Microvascular Changes Overlying Choroidal Nodules in Neurofibromatosis Type 1”. Case Rep Ophthalmol. 8 (1): 214–220. doi:10.1159/000469702. PMC 5422752. PMID 28512424.
- ↑ Evans, D G. R (2000). “Neurofibromatosis type 2”. Journal of Medical Genetics. 37 (12): 897–904. doi:10.1136/jmg.37.12.897. ISSN 1468-6244.
- ↑ 6.0 6.1 Plouin PF, Perdu J, La Batide-Alanore A, Boutouyrie P, Gimenez-Roqueplo AP, Jeunemaitre X (2007). “Fibromuscular dysplasia”. Orphanet J Rare Dis. 2: 28. doi:10.1186/1750-1172-2-28. PMC 1899482. PMID 17555581.
- ↑ Gazit Y, Jacob G, Grahame R (2016). “Ehlers-Danlos Syndrome-Hypermobility Type: A Much Neglected Multisystemic Disorder”. Rambam Maimonides Med J. 7 (4). doi:10.5041/RMMJ.10261. PMC 5101008. PMID 27824552.
- ↑ Michet CJ, Matteson EL (2008). “Polymyalgia rheumatica”. BMJ. 336 (7647): 765–9. doi:10.1136/bmj.39514.653588.80. PMC 2287267. PMID 18390527.
- ↑ Baker KR, Rice L (2012). “The amyloidoses: clinical features, diagnosis and treatment”. Methodist Debakey Cardiovasc J. 8 (3): 3–7. PMC 3487569. PMID 23227278.
- ↑ Howard T, Ahmad K, Swanson JA, Misra S (2014). “Polyarteritis nodosa”. Tech Vasc Interv Radiol. 17 (4): 247–51. doi:10.1053/j.tvir.2014.11.005. PMC 4363102. PMID 25770638.
- ↑ Sharma A, Sharma K (September 2013). “Hepatotropic viral infection associated systemic vasculitides-hepatitis B virus associated polyarteritis nodosa and hepatitis C virus associated cryoglobulinemic vasculitis”. J Clin Exp Hepatol. 3 (3): 204–12. doi:10.1016/j.jceh.2013.06.001. PMC 4216827. PMID 25755502.
- ↑ Takahashi K, Oharaseki T, Yokouchi Y (2011). “Pathogenesis of Kawasaki disease”. Clin Exp Immunol. 164 Suppl 1: 20–2. doi:10.1111/j.1365-2249.2011.04361.x. PMC 3095860. PMID 21447126.
- ↑ Heegaard ED, Brown KE (2002). “Human parvovirus B19”. Clin Microbiol Rev. 15 (3): 485–505. PMC 118081. PMID 12097253.
- ↑ Basetti S, Hodgson J, Rawson TM, Majeed A (2017). “Scarlet fever: a guide for general practitioners”. London J Prim Care (Abingdon). 9 (5): 77–79. doi:10.1080/17571472.2017.1365677. PMC 5649319. PMID 29081840.
- ↑ Vostral SL (2011). “Rely and Toxic Shock Syndrome: a technological health crisis”. Yale J Biol Med. 84 (4): 447–59. PMC 3238331. PMID 22180682.
- ↑ Balfour HH, Dunmire SK, Hogquist KA (2015). “Infectious mononucleosis”. Clin Transl Immunology. 4 (2): e33. doi:10.1038/cti.2015.1. PMC 4346501. PMID 25774295.
- ↑ Levett PN (April 2001). “Leptospirosis”. Clin. Microbiol. Rev. 14 (2): 296–326. doi:10.1128/CMR.14.2.296-326.2001. PMC 88975. PMID 11292640.
- ↑ Biesiada G, Czepiel J, Leśniak MR, Garlicki A, Mach T (2012). “Lyme disease: review”. Arch Med Sci. 8 (6): 978–82. doi:10.5114/aoms.2012.30948. PMC 3542482. PMID 23319969.
- ↑ White SJ, Boldt KL, Holditch SJ, Poland GA, Jacobson RM (2012). “Measles, mumps, and rubella”. Clin Obstet Gynecol. 55 (2): 550–9. doi:10.1097/GRF.0b013e31824df256. PMC 3334858. PMID 22510638.
- ↑ Walker DH (1989). “Rocky Mountain spotted fever: a disease in need of microbiological concern”. Clin Microbiol Rev. 2 (3): 227–40. PMC 358117. PMID 2504480.
- ↑ Mishra AK, Yadav P, Mishra A (2016). “A Systemic Review on Staphylococcal Scalded Skin Syndrome (SSSS): A Rare and Critical Disease of Neonates”. Open Microbiol J. 10: 150–9. doi:10.2174/1874285801610010150. PMC 5012080. PMID 27651848.
- ↑ Hoetzenecker W, Mehra T, Saulite I, Glatz M, Schmid-Grendelmeier P, Guenova E; et al. (2016). “Toxic epidermal necrolysis”. F1000Res. 5. doi:10.12688/f1000research.7574.1. PMC 4879934. PMID 27239294.
- ↑ MacGowan SW, Sidhu P, Aherne T, Luke D, Wood AE, Neligan MC, McGovern E (June 1993). “Atrial myxoma: national incidence, diagnosis and surgical management”. Ir J Med Sci. 162 (6): 223–6. PMID 8407260.
- ↑ Avci G, Akoz T, Gul AE (2009). “Cutaneous cholesterol embolization”. J Dermatol Case Rep. 3 (2): 27–9. doi:10.3315/jdcr.2009.1031. PMC 3157794. PMID 21886725.
- ↑ Chao, Christine (2009). “Segmental Arterial Mediolysis”. Seminars in Interventional Radiology. 26 (03): 224–232. doi:10.1055/s-0029-1225666. ISSN 0739-9529.
- ↑ Chaturvedi S, McCrae KR (2015). “The antiphospholipid syndrome: still an enigma”. Hematology Am Soc Hematol Educ Program. 2015: 53–60. doi:10.1182/asheducation-2015.1.53. PMC 4877624. PMID 26637701.
- ↑ Espinosa M, Gottlieb BS (July 2012). “Juvenile idiopathic arthritis”. Pediatr Rev. 33 (7): 303–13. doi:10.1542/pir.33-7-303. PMID 22753788.
- ↑ Chung SA, Seo P (2010). “Microscopic polyangiitis”. Rheum Dis Clin North Am. 36 (3): 545–58. doi:10.1016/j.rdc.2010.04.003. PMC 2917831. PMID 20688249.
- ↑ Kubaisi B, Abu Samra K, Foster CS (2016). “Granulomatosis with polyangiitis (Wegener’s disease): An updated review of ocular disease manifestations”. Intractable Rare Dis Res. 5 (2): 61–9. doi:10.5582/irdr.2016.01014. PMC 4869584. PMID 27195187.
- ↑ Keogh KA, Specks U (April 2006). “Churg-Strauss syndrome”. Semin Respir Crit Care Med. 27 (2): 148–57. doi:10.1055/s-2006-939518. PMID 16612766.
- ↑ Keasberry J, Frazier J, Isbel NM, Van Eps CL, Oliver K, Mudge DW (2013). “Hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis presenting with a vasculitic syndrome, acute nephritis and a puzzling skin rash: a case report”. J Med Case Rep. 7: 20. doi:10.1186/1752-1947-7-20. PMC 3565908. PMID 23316942.
- ↑ McAdoo SP, Pusey CD (July 2017). “Anti-Glomerular Basement Membrane Disease”. Clin J Am Soc Nephrol. 12 (7): 1162–1172. doi:10.2215/CJN.01380217. PMID 28515156.
- ↑ Ferri C, Mascia MT (January 2006). “Cryoglobulinemic vasculitis”. Curr Opin Rheumatol. 18 (1): 54–63. PMID 16344620.
- ↑ Guo QY, Wu M, Wang YW, Sun GD (2017). “Hepatitis C virus-associated cryoglobulinemia with membrano-proliferative glomerulonephritis treated with prednisolone and interferon: A case report”. Exp Ther Med. 14 (2): 1395–1398. doi:10.3892/etm.2017.4671. PMC 5525644. PMID 28810602.
- ↑ Farhadian JA, Castilla C, Shvartsbeyn M, Meehan SA, Neimann A, Pomeranz MK (December 2015). “IgA vasculitis (Henoch-Schönlein purpura)”. Dermatol. Online J. 21 (12). PMID 26990342.
- ↑ Buck A, Christensen J, McCarty M (2012). “Hypocomplementemic urticarial vasculitis syndrome: a case report and literature review”. J Clin Aesthet Dermatol. 5 (1): 36–46. PMC 3277093. PMID 22328958.
- ↑ Sise MJ (February 2014). “Acute mesenteric ischemia”. Surg. Clin. North Am. 94 (1): 165–81. doi:10.1016/j.suc.2013.10.012. PMID 24267504.
- ↑ McDonald JR (2009). “Acute infective endocarditis”. Infect Dis Clin North Am. 23 (3): 643–64. doi:10.1016/j.idc.2009.04.013. PMC 2726828. PMID 19665088.
- ↑ Einhorn J, Levis JT (2015). “Dermatologic Diagnosis: Leukocytoclastic Vasculitis”. Perm J. 19 (3): 77–8. doi:10.7812/TPP/15-001. PMC 4500485. PMID 26176572.
- ↑ Margo CE, Goldman DR (2008). “Langerhans cell histiocytosis”. Surv Ophthalmol. 53 (4): 332–58. doi:10.1016/j.survophthal.2008.04.007. PMID 18572052.
- ↑ Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008). “Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship”. Mayo Clin Proc. 83 (5): 584–94. doi:10.4065/83.5.584. PMC 2718421. PMID 18452692.
- ↑ Jackman DM, Johnson BE (2005). “Small-cell lung cancer”. Lancet. 366 (9494): 1385–96. doi:10.1016/S0140-6736(05)67569-1. PMID 16226617.
- ↑ Parambil JG, Savci CD, Tazelaar HD, Ryu JH (April 2005). “Causes and presenting features of pulmonary infarctions in 43 cases identified by surgical lung biopsy”. Chest. 127 (4): 1178–83. doi:10.1378/chest.127.4.1178. PMID 15821192.
- ↑ VanDeVoorde RG (January 2015). “Acute poststreptococcal glomerulonephritis: the most common acute glomerulonephritis”. Pediatr Rev. 36 (1): 3–12, quiz 13. doi:10.1542/pir.36-1-3. PMID 25554106.
- ↑ Corrigan JJ, Boineau FG (November 2001). “Hemolytic-uremic syndrome”. Pediatr Rev. 22 (11): 365–9. PMID 11691946.
- ↑ Byrd JC, Stilgenbauer S, Flinn IW (2004). “Chronic lymphocytic leukemia”. Hematology Am Soc Hematol Educ Program: 163–83. doi:10.1182/asheducation-2004.1.163. PMID 15561682.
- ↑ Michels TC, Petersen KE (March 2017). “Multiple Myeloma: Diagnosis and Treatment”. Am Fam Physician. 95 (6): 373–383. PMID 28318212.
- ↑ Klion A (2009). “Hypereosinophilic syndrome: current approach to diagnosis and treatment”. Annu. Rev. Med. 60: 293–306. doi:10.1146/annurev.med.60.062107.090340. PMID 19630574.
- ↑ Shankland KR, Armitage JO, Hancock BW (September 2012). “Non-Hodgkin lymphoma”. Lancet. 380 (9844): 848–57. doi:10.1016/S0140-6736(12)60605-9. PMID 22835603.
- ↑ Lin RY (January 1986). “Serum sickness syndrome”. Am Fam Physician. 33 (1): 157–62. PMID 2867672.
- ↑ Venugopal A (2014). “Disseminated intravascular coagulation”. Indian J Anaesth. 58 (5): 603–8. doi:10.4103/0019-5049.144666. PMC 4260307. PMID 25535423.
- ↑ Nomura S (2016). “Advances in Diagnosis and Treatments for Immune Thrombocytopenia”. Clin Med Insights Blood Disord. 9: 15–22. doi:10.4137/CMBD.S39643. PMC 4948655. PMID 27441004.
- ↑ Chiarchiaro J, Chen BB, Gibson KF (2016). “New molecular targets for the treatment of sarcoidosis”. Curr Opin Pulm Med. 22 (5): 515–21. doi:10.1097/MCP.0000000000000304. PMC 5152532. PMID 27454074.
- ↑ Murdoch DR (January 2003). “Diagnosis of Legionella infection”. Clin. Infect. Dis. 36 (1): 64–9. doi:10.1086/345529. PMID 12491204.
- ↑ Tsokos, George C. (2011). “Systemic Lupus Erythematosus”. New England Journal of Medicine. 365 (22): 2110–2121. doi:10.1056/NEJMra1100359. ISSN 0028-4793.
- ↑ Scott JT (1991). “The gold standard in rheumatoid arthritis”. J R Soc Med. 84 (9): 513–4. PMC 1293405. PMID 1682491.
- ↑ Emmungil H, Aydın SZ (2015). “Relapsing polychondritis”. Eur J Rheumatol. 2 (4): 155–159. doi:10.5152/eurjrheum.2015.0036. PMC 5047229. PMID 27708954.
- ↑ Yazici H, Fresko I, Yurdakul S (March 2007). “Behçet’s syndrome: disease manifestations, management, and advances in treatment”. Nat Clin Pract Rheumatol. 3 (3): 148–55. doi:10.1038/ncprheum0436. PMID 17334337.
- ↑ Iliescu DA, Timaru CM, Batras M, De Simone A, Stefan C (2015). “COGAN’S SYNDROME”. Rom J Ophthalmol. 59 (1): 6–13. PMC 5729811. PMID 27373108.
- ↑ Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF (2016). “Inflammatory Bowel Disease”. Dtsch Arztebl Int. 113 (5): 72–82. doi:10.3238/arztebl.2016.0072. PMC 4782273. PMID 26900160.
- ↑ Dutly F, Altwegg M (2001). “Whipple’s disease and “Tropheryma whippelii““. Clin Microbiol Rev. 14 (3): 561–83. doi:10.1128/CMR.14.3.561-583.2001. PMC 88990. PMID 11432814.
- ↑ Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dörner T (2017). “The Diagnosis and Treatment of Sjögren’s Syndrome”. Dtsch Arztebl Int. 114 (20): 354–361. doi:10.3238/arztebl.2017.0354. PMC 5471601. PMID 28610655.
- ↑ Benseler SM, Silverman E, Aviv RI, Schneider R, Armstrong D, Tyrrell PN, deVeber G (April 2006). “Primary central nervous system vasculitis in children”. Arthritis Rheum. 54 (4): 1291–7. doi:10.1002/art.21766. PMID 16575852.
- ↑ Latgé JP (1999). “Aspergillus fumigatus and aspergillosis”. Clin Microbiol Rev. 12 (2): 310–50. PMC 88920. PMID 10194462.
- ↑ Guimarães AJ, Nosanchuk JD, Zancopé-Oliveira RM (2006). “DIAGNOSIS OF HISTOPLASMOSIS”. Braz J Microbiol. 37 (1): 1–13. doi:10.1590/S1517-83822006000100001. PMC 2863343. PMID 20445761.
- ↑ Sköldenberg B (1996). “Herpes simplex encephalitis”. Scand J Infect Dis Suppl. 100: 8–13. PMID 9163027.
- ↑ Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi JM (2011). “Pre-eclampsia: pathophysiology, diagnosis, and management”. Vasc Health Risk Manag. 7: 467–74. doi:10.2147/VHRM.S20181. PMC 3148420. PMID 21822394.
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Overview
The prevalence of cryoglobulinemia is approximately 1 per 100,000 individuals worldwide. The mean age reported is 42-52 years. It is more prevalent in females as compared to males, the ratio being 3:1.
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
Prevalence
- The prevalence of cryoglobulinemia is approximately 1 per 100,000 individuals worldwide.[1]
Case Fatality Rate
Age
- The mean age reported is 42-52 years.
Gender
- Cryoglobulinemia is more prevalent in females as compared to males.[2]
- The ratio is 3:1.
Region
- The majority of cryoglobulinemia cases are reported in Mediterranean basin.
References
- ↑ Gorevic PD, Kassab HJ, Levo Y, Kohn R, Meltzer M, Prose P; et al. (1980). “Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients”. Am J Med. 69 (2): 287–308. PMID 6996482.
- ↑ Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M (1974). “Biologic and clinical significance of cryoglobulins. A report of 86 cases”. Am J Med. 57 (5): 775–88. PMID 4216269.
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Overview
Common risk factors of cryoglobulemia are certain malignancies, autoimmune diseases and infections. Among these, leukemia, multiple myeloma, rheumatoid arthritis, hepatitis B, cytomegalovirus are more commonly seen risk factors in patients having cryoglobulemia. Other risk factors that contribute to cryoglobulinemia are epstein-Barr virus, human parvovirus B19 and mycoplasma pneumonia.
Risk Factors
Type I cryoglobulinemia is most often related to hematologic malignancies.
Types II and III are most often found in people who have a chronic (long-lasting) inflammatory condition, such as an autoimmune disease or infections such as hepatitis C. Most patients with mixed cryoglobulinemia have a chronic hepatitis C infection.
Common risk factors
The common risk factors of cryoglobulemia are as follows:[1][2][3]
Malignancy:
- Leukemia
- Multiple myeloma
- Mycoplasma pneumonia
- Primary macroglobulinemia
Autoimmune disorders:
Infections:
- Hepatitis B
- Cytomegalovirus
- Epstein-Barr virus
- Human parvovirus B19
References
- ↑ Belizna CC, Hamidou MA, Levesque H, Guillevin L, Shoenfeld Y (2009). “Infection and vasculitis”. Rheumatology (Oxford). 48 (5): 475–82. doi:10.1093/rheumatology/kep026. PMID 19258377.
- ↑ Rodríguez-Pla A, Stone JH (2006). “Vasculitis and systemic infections”. Curr Opin Rheumatol. 18 (1): 39–47. PMID 16344618.
- ↑ Fabris P, Tositti G, Giordani MT, Romanò L, Betterle C, Pignattari E; et al. (2003). “Prevalence and clinical significance of circulating cryoglobulins in HIV-positive patients with and without co-infection with hepatitis C virus”. J Med Virol. 69 (3): 339–43. doi:10.1002/jmv.10294. PMID 12526043.
Screening
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Overview
Natural History
Complications
The complications of cryoglobulinemia are as follows:
- Rapidly progressive neuropathy
- Heart failure
- Digital ischemia threatening amputation
- Diffuse alveolar hemorrhage resulting in hemoptysis
- Respiratory failure
- Stroke
- End stage renal disease
Prognosis
Patients having severe manifestations of the disease such as pulmonary vasculitis, end-stage renal disease, cardiac vasculitis and central nervous system vasculitis have generally poor prognosis of the disease. The prognosis of cryoglobulinemia depends on the organ system involved and varies accordingly.
| Organ system involved | Survival rate |
|---|---|
| Glomerulonephritis | 79% |
| Pulmonary vasculitis | 22% |
| Central nervous system vasculitis | 66% |
| Gastrointestinal vasculitis | 67% |
| Cardiac vasculitis | 100% |
References
Diagnosis
Diagnosis
Diagnostic Study of Choice | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X Ray | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Acknowledgements
Acknowledgements
The content on this page was first contributed by: Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
